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Postoperative atrial fibrillation (POAF) is the most com-
mon complication following cardiac surgery with an inci-
dence of 18.5–40 % [1–4]. It is important to prevent POAF
because it can lead to hemodynamic instability and the risk
of cerebral infarction. Various factors are involved in the
onset of POAF, among which those most strongly corre-
lated with it are inflammation, fibrosis, and the fluid bal-
ance. We previously reported that advanced age and
associated cardiac fibrosis have a strong influence, and that
preventive treatment is needed for patients with severe
fibrosis [5]. Regarding the prevention of POAF, adminis-
tration of amiodarone and oral administration of beta-
blockers are recommended in the ACC/AHA/ESC guide-
lines [6]. However, there are no Japanese guidelines for the
prevention of POAF.
We have previously demonstrated that landiolol hydro-
chloride, an ultra-short-acting intravenous b-blocker, and
oral b-blocker bisoprolol can prevent POAF in a random-
ized controlled trial of patients undergoing CABG with
cardiopulmonary bypass, and we concluded that an anti-
inflammatory effect, anti-ischemic action, and sympatho-
lytic effect were involved [7, 8].
A study by Suezawa et al. (‘‘Clinical benefits of meth-
ylprednisolone in off-pump coronary artery bypass sur-
gery’’) was recently published in General Thoracic and
Cardiovascular Surgery. They reported that methylpred-
nisolone inhibits inflammation and thus decreases POAF in
patients undergoing off-pump coronary artery bypass
grafting (OPCAB) [9].
Because patients who require cardiac surgery are often
elderly, inflammation caused by the oxygenator and sudden
activation of the renin–angiotensin–aldosterone system
contribute to creating conditions that favor the onset of
POAF. Although steroids can be useful from the perspec-
tive of suppressing inflammation caused by the oxygenator,
the need for steroid therapy remains controversial, because
the study by Suezawa et al. was performed in OPCAB
subjects. In Europe, a long-acting steroid is often admin-
istered perioperatively for prophylaxis in patients under-
going cardiac surgery with an oxygenator. However, there
is insufficient evidence that steroids can prevent major
adverse events. In the USA, routine perioperative admin-
istration of steroids is not done in consideration of the
possible risk of adverse events [10, 11].
There have been many investigations into the efficacy of
steroid therapy for patients undergoing cardiac surgery
using cardiopulmonary bypass, but conclusive evidence
has not been obtained. A multicenter randomized trial of
high-dose intravenous steroid administration during cardiac
surgery with an oxygenator showed that the incidence of
major adverse events up to 30 days was not decreased in
adult cardiac surgery patients treated with dexamethasone.
There was also no difference in the incidence of atrial
fibrillation, which was 33.1 % in the dexamethasone group
versus 35.2 % in the placebo group. In addition, the sub-
group analysis of events (death up to 30 days, myocardial
infarction, stroke, renal failure, and respiratory failure)
showed that the incidence among patients younger than
65 years was significantly lower in the dexamethasone
group, but the risk of events tended to increase among
patients older than 80 years who are susceptible to POAF
[12]. Inflammatory factors such as cytokines are reduced in
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OPCAB compared with cardiac surgery using an oxygen-
ator, so the clinical significance of using steroids is still
open to question.
Although the report by Suezawa et al. is significant for
the future perioperative management of OPCAB, there are
four issues to consider. First, they performed a small-scale
study in 30 subjects, and the number of subjects was not
sufficient to assess the influences on POAF in statistical
terms. Second, although use of b-blockers is recommended
by the ACC/AHA/ESC guidelines, only 27 % of the
patients in Group C, and 20 % of those in Group M used
b-blockers preoperatively and there were no data on peri-
operative/postoperative b-blocker use. In addition, they did
not discuss the recent report that the anti-inflammatory
effect of statins can prevent POAF. Third, in spite of per-
forming OPCAB, the incidence of POAF was 47 % in
Group C, which was higher than previously reported. Also,
40 % of the subjects underwent postoperative pleural
drainage in Group C, which was considered to be a very
high rate for OPCAB that has generally been reported to be
less invasive. The fourth point is the risk of adverse reac-
tions to steroids. Administration of steroid is not always
appropriate for patients undergoing cardiac surgery, but the
issues regarding steroids and the patients who are inap-
propriate for steroid therapy were not described. Although
it may have been difficult to discuss these points due to the
small number of subjects, we hope that appropriate use of
steroids will be better defined in the future.
However, despite the above issues, the study by Suez-
awa et al. is important because it suggested the possibility
of preventing POAF in patients undergoing OPCAB. Ste-
roids have the advantage of being able to inhibit stress of
surgery potently, and the advantage is considered as the
major factor in preventing POAF. Steroids are expected to
be a new prophylaxis of POAF in patients undergoing
OPCAB when optimal dose and indicated patients will be
demonstrated in larger number of subjects in the future.
Because POAF has an influence during the perioperative
period as well as on the long-term prognosis, we consider
that there is an urgent need to prepare Japanese guidelines
for its prevention.
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